Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.67 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.67 |
| ▸ | AR | P10275 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | AHR | P35869 | 1/20 | 0.60 |
| ▸ | GMNN | O75496 | 1/20 | 0.60 |
| ▸ | RAF1 | P04049 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7374618 | 0.90 | ALDH1A1 (0.82) | ALDH1A1HPGDCYP3A4MAPTKDM4E | |
| SCHEMBL4649947 | 0.86 | CYP3A4 (0.76) | ALDH1A1HPGDCYP3A4MAPTKDM4E | |
| SCHEMBL21822841 | 0.86 | ALDH1A1 (0.74) | ALDH1A1HPGDCYP3A4MAPTKDM4E | |
| 8-Methoxyflavone SCHEMBL26180800 | 0.85 | ALDH1A1 (0.74) | ALDH1A1HPGDCYP3A4MAPTKDM4E | |
| SCHEMBL7378571 | 0.85 | ALDH1A1 (0.73) | ALDH1A1HPGDCYP3A4MAPTKDM4E | |
| SCHEMBL6616218 | 0.85 | CYP3A4 (0.73) | ALDH1A1HPGDCYP3A4MAPTKDM4E | |
| SCHEMBL253522 | 0.84 | HPGD (0.78) | ALDH1A1HPGDCYP3A4MAPTKDM4E | |
| SCHEMBL12835507 | 0.83 | ALDH1A1 (0.70) | ALDH1A1HPGDCYP3A4MAPTKDM4E | |
| SCHEMBL8934643 | 0.79 | ALDH1A1 (0.65) | ALDH1A1HPGDCYP3A4MAPTKDM4E | |
| SCHEMBL6801603 | 0.79 | CYP3A4 (0.65) | ALDH1A1HPGDCYP3A4MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200120909-A1 | COMPOSITIONS AND METHODS FOR THE STUDY AND TREATMENT OF ACUTE KIDNEY INJURY | THE JOHNS HOPKINS UNIVERSITY | 2020-04-23 | — | — | US | disclosed |
| US-20160120158-A1 | COMPOSITIONS AND METHODS FOR THE STUDY AND TREATMENT OF ACUTE KIDNEY INJURY | UNIV JOHNS HOPKINS (US) | 2016-05-05 | — | — | US | disclosed |
| US-20150080462-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATING TO OXIDATIVE STRESS | UNIV JOHNS HOPKINS (US) | 2015-03-19 | — | — | US | disclosed |
| US-20140186277-A1 | Methods and Compositions for Reducing Skin Damage | SHISEIDO CO., LTD. (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20140080795-A1 | NRF2 Deficiency Influences Susceptibility to Steroid Resistance via HDAC2 Reduction | UNIVERSITY OF ROCHESTER (US) | 2014-03-20 | — | — | US | disclosed |
| WO-2012068454-A2 | NRF2 DEFICIENCY INFLUENCES SUSCEPTIBILITY TO STEROID RESISTANCE VIA HDAC2 REDUCTION | UNIVERSITY OF ROCHESTER (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120029071-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING RADIATION INJURY | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110250300-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATING TO OXIDATIVE STRESS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-13 | — | — | US | disclosed |
| EP-2362770-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING RADIATION INJURY | The Johns Hopkins University (US) | 2011-09-07 | — | — | EP | disclosed |
| US-20110091387-A1 | METHODS AND COMPOSITIONS FOR REDUCING SKIN DAMAGE | THE GENERAL HOSPITAL CORPORATION (US) | 2011-04-21 | — | — | US | disclosed |
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010059245-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING RADIATION INJURY | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-05-27 | — | — | WO | disclosed |
| US-20090269772-A1 | SYSTEMS AND METHODS FOR IDENTIFYING COMBINATIONS OF COMPOUNDS OF THERAPEUTIC INTEREST | THERASIS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | GOLT1B, NPC1L1, NPC1 | ALDH1A1 3582/4885HPGD 4457/4885CYP3A4 4800/4885 |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | ALDH1A1 860/4885HPGD 503/4885CYP3A4 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.